New Normal Labs ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  15.2% 10.9% 9.9% 9.5% 6.2%  
Credit score (0-100)  14 22 23 25 37  
Credit rating  BB BB BB BB BBB  
Credit limit (kDKK)  -0.0 -0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 5.9 -19.4 32.6 -17.3  
EBITDA  -22.6 5.9 -19.4 32.6 -17.3  
EBIT  -22.6 5.9 -19.4 32.6 -17.3  
Pre-tax profit (PTP)  -22.6 5.9 -19.5 32.3 -17.6  
Net earnings  -22.6 5.9 -19.5 32.3 -17.6  
Pre-tax profit without non-rec. items  -22.6 5.9 -19.5 32.3 -17.6  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -22.6 -16.6 4.0 36.3 18.7  
Interest-bearing liabilities  21.8 27.2 20.9 21.5 32.0  
Balance sheet total (assets)  1.3 19.2 64.5 64.9 260  

Net Debt  21.0 20.5 -1.5 15.1 9.8  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 5.9 -19.4 32.6 -17.3  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1 19 64 65 260  
Balance sheet change%  0.0% 1,397.1% 236.5% 0.6% 300.1%  
Added value  -22.6 5.9 -19.4 32.6 -17.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 1.0 -1.0 1.0 -1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -94.6% 19.8% -38.7% 50.5% -10.7%  
ROI %  -103.4% 24.2% -74.5% 78.9% -32.0%  
ROE %  -1,763.0% 57.9% -168.4% 160.1% -64.1%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -94.6% -46.5% 6.2% 56.0% 7.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -93.3% 346.1% 7.7% 46.2% -56.8%  
Gearing %  -96.7% -163.1% 519.9% 59.2% 170.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.5% 1.6% 1.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.1 0.5 1.0 1.4 0.1  
Current Ratio  0.1 0.5 1.0 1.4 0.1  
Cash and cash equivalent  0.8 6.7 22.4 6.4 22.1  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -22.6 -16.6 1.5 11.3 -206.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0